In a small single center study (n = 316) of newly diagnosed IBC between 1989–2008, HR−/HER2+ had inferior survival to HR+/HER2+ and HR+/HER2− [54]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.